New tuberculosis vaccine development.
Tuberculosis (TB) is a devastating disease that kills more than three million people each year. Of these, 0.9 million are co-infected with HIV and numbers of infections and death continue to rise with the global spread of HIV. A new vaccine is desperately needed to control this epidemic that threatens to kill 90 million people over the next 3 decades. Outstanding work in research laboratories, combined with the success of genome sequencing, has resulted in a variety of candidate TB vaccines, many of which are sufficiently promising to advance into clinical trials. This review discusses the array of new candidate TB vaccines and the clinical studies that are currently planned.
Sacksteder
Katherine A
KA
Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850, USA.
Nacy
Carol A
CA
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007114:Immunization; D014376:Tuberculosis / Q000453:epidemiology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology
D001500:BCG Vaccine; D032581:Tuberculosis Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated